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1. Introduction  
Glucocorticoids are hormones synthesized from cholesterol in the cortex of adrenal glands. 
Synthetic glucocorticoids are chemical derivatives synthesized from cholic acid obtained 
from cattle or steroid sapogenins.  The chemical structure of these drugs is very similar to 
that of natural glucocorticoids. Therefore, the synthetic derivatives efficiently bind to 
intracellular receptors of glucocorticoid and mineralocorticoid, which promote a myriad of 
transcriptional and non-transcriptional processes.  Synthetic glucocorticoids can trigger a 
cascade of events including neurotransmitter modulation, protein expression, neuronal 
firing or neurite growth.  In addition, these substances are some of the most potent 
antiinflammatory and immunosuppressive agents available in human medicine with a good 
drug safety profile in humans.  Thus, they are a valuable pharmacological tool for the 
treatment of acute and chronic neuroinflammation, and autoimmune disorders with 
neurological involvement.  However, increasing evidence indicates that a high-dose or a 
long-term delivery of synthetic glucocorticoids may promote cognitive dysfunction, 
memory impairment, apoptosis, systemic hypersensitivity, urticaria-angioedema, neuronal 
degeneration, cerebral atrophy, major depression or steroid psychosis.  Yet, these major side 
effects are relatively infrequent, the unrestricted use of glucocorticoids has to be avoided 
and systematic neuropsychological assessments are recommended to detect early 
neurological impairment. Herein, we discuss the mechanisms by which synthetic 
glucocorticoids may induce neural degeneration and other pathological changes in different 
brain regions. In addition, we describe the role of glucocorticoids in some autoimmune 
neurological disorders. 
2. Glucocorticoids 
The hypothalamus-pituitary-adrenal axis exerts an important regulation on neural functions 
mediated by the releasing of steroid molecules named corticosteroids.  These hormones are 
synthesized from cholesterol in the cortex of adrenal glands (Fietta et al., 2009; Nicolaides et 
al., 2010).  Two types of corticoids have been identified: glucocorticoids and 
mineralocorticoids.  Glucocorticoids are produced in the inner region of the adrenal cortex 
(fascicular zone), while mineralocorticoids are synthesized in the outer part of the adrenal 
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cortex (glomerular zone) (Schimmer & George 1998).  The name mineralocorticoid derives 
from early observations that associated these hormones with the homeostasis of sodium and 
water, whereas glucocorticoids obtained their name from initial observations that these 
steroids were involved in the metabolism of glucose.  To date, it is well accepted that gluco- 
and mineralocorticoids have a number of pleiotropic and systemic effects (Figure 1) on 
cardiovascular system (Schimmer & George 1998; Ullian 1999), erythropoiesis (Amylon et al. 
1986; King et al. 1988), calcium and bone metabolism (Thacker 2010), gastrointestinal tract 
(Black 1988), nitrogen excretion and glucose metabolism (Schimmer & George 1998), and 
exert a strong regulation in the immune system (Silverman et al. 2005). These physiological 
properties of glucocorticoids are useful in clinical medicine to treat and control a broad 
spectrum of diseases, such as: allergies, autoimmune diseases, cancer, hormonal 
replacement, asthma and sepsis.  Nevertheless, glucocorticoids also have potentially 
harmful effects on several body systems, including the central nervous system.  Some of 
these neurological impairments will be discussed below. 
 
 
Fig. 1. Physiological effects of glucocorticoids and the hypothalamus-pituitary-adrenal axis.  
CRF = corticotropin-releasing factor ;  ACTH = adrenocorticotrophin hormone;  (+) indicates 
stimulation and (-) indicates inhibition. 
3. Synthetic glucocorticoids 
Synthetic glucocorticoids are usually synthesized from cholic acid obtained from cattle or 
steroid sapogenins found in plants.  The chemical structure of these drugs is slightly 
different from that of natural glucocorticoids (Figure 2 A - B).  For example, prednisolone 
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differs from cortisol only by a δ-1-dihydro configuration.  Instead, bexamethasone and 
betamethasone have additional 9-ǂ-fluoro and 16-ǃ- or 16-ǂ-methyl groups, respectively 
(Tegethoff et al. 2009).  
 
 
Fig. 2. Chemical structures of glucocorticoids.  A. Metabolic pathways in the adrenocortical 
hormone biosynthesis. B. Synthetic glucocorticoids with anti-inflammatory and 
immunosuppressive activity. 
Endogenous and synthetic glucocorticoids regulate a number of physiological and 
behavioural responses via intracellular receptors, which modulate the function of neural 
cells.   In several brain regions, neural cells express two types of corticoid receptors:  Type-1 
receptors, also called mineralocorticoid receptors (MRs), and Type-2 receptors, also called 
glucocorticoid receptors (GRs) or NR3C1 (nuclear receptor subfamily 3, group C, member 1) 
(Fietta et al. 2009; Hoppmann et al. 2010; Marques et al. 2009; Prager et al. 2010).  NR3C1 
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mediates the negative feedback in the HPA axis and in other limbic structures (de Kloet 
2003; De Kloet et al. 1998).   GRs have tenfold lesser affinity for corticosteroids than MRs 
(Table 1).  The physiological outcome of these interactions is that GRs are mainly active 
during periods of abundant glucocorticoid secretion, such as circadian peak, systemic 
inflammation or stress.  Thus, some of the functions of GRs include the regulation of energy 
metabolism, cellular homeostasis, stress-induced response, information storage and retrieval 
(de Kloet 2003; de Kloet et al. 1999; De Kloet et al. 1998).  In contrast, MRs have a high 
affinity for corticosteroids; as a result, they are active when circulating glucocorticoid levels 
are relatively low. These receptors are highly expressed in hippocampus, septum, amygdala, 
frontal cortex, hypothalamic paraventricular nucleus and locus coeruleus (de Kloet 2003; De 
Kloet et al. 1998).  One of the main functions of MRs is the regulation of basal HPA tone (de 
Kloet 2003; De Kloet et al. 1998).   
 
Characteristics 11β-HSD1 11β-HSD2
Molecular mass 34 kDa 40 kDa
Activity (Km) Low affinity
Cortisol: 17 mM 
Corticosterone: 20 mM 
Cortisone: 200 mM
High affinity
Cortisol:12 nM 
Corticosterone: 45 nM 
Dexamethasone: 140 nM 
Inhibitors Glycerhetinic acid
Carbenoxolone
Table 1. Glucocorticoid affinity in type-1 (11ǃ-HSD1) and type-2 receptors (11ǃ-HSD2).  
Modified from Buckingham 2006. 
 
Glucocorticoid Plasma half-life Potency 
Cortisol 
Cortisone 
Hydrocortisone 
Short 
t1/2 8-12 h 
0.8 
1 
0.8 
Deflazacort 
Prednisone 
Prednisolone 
Methylprednisolone 
Triamcinolone 
Intermediate 
t1/2 12-36 h 
5 
4 
4 
5 
5 
Dexamethasone
Betamethasone 
Long 
t1/2 36–72 h 
25 
30-40 
Table 2. Potency and plasma half-life of natural and synthetic glucocorticoids commonly 
used in medicine. 
The pharmacological effects of natural and synthetic glucocorticoids are mediated by the same 
genomic and non-genomic pathways (Buckingham 2006; Lowenberg et al. 2005; Lowenberg et 
al. 2006).  The levels of efficacy, potency and pharmacological activity of synthetic hormones 
are determined by their pharmacokinetic properties (Table 2) (Fietta et al. 2009; Gonzalez-
Perez et al. 2007).  In clinic, synthetic glucocorticoids are commonly used as anti-inflammatory 
drugs for the treatment of allergies, rheumatic diseases, asthma, lymphoproliferative diseases 
and autoimmune disorders (Liberman et al. 2010).  Most, if not all, of them can bind to both 
MRs and GRs, but with different affinities (Gonzalez-Perez et al. 2007). Remarkably, an 
increasing number of pre-clinical and clinical studies indicate that synthetic glucocorticoids 
can modify the citoarchitecture and function of glial cells, which alter the brain homeostasis. 
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Fig. 3. Astrocytes modulate and/or promote several effects into the brain under the 
influence of glucocorticoids. Corticoids (GCs); glucocorticoid receptor (GR); 
mineralocorticoid receptor (MR). 
www.intechopen.com
 Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights 
 
328 
4. Effects of synthetic glucocorticoids on astroglia 
GRs and MRs are expressed not only by neurons, but also by glial cells or neuroglia (Bohn et 
al. 1991; Vielkind et al. 1990). Glial cells are non-neuronal cells that preserve neural 
homeostasis, form myelin, and provide support and protection for neurons.  In fact, 
corticoids exert several effects into the brain by targeting glial cells that, in turn, modify the 
cerebral functioning (Figure 3). Astrocytes, collectively known as astroglia, are the most 
abundant glial cells and play multiple roles into the brain, such as: Neurotransmitter 
reuptake and release, modulation of synaptic transmission, nervous system repair, 
hormonal signalling, vascular tone regulation, preservation of blood–brain barrier and, in 
some cases, astrocytes may function as neural stem cells (Gonzalez-Perez & Alvarez-Buylla 
2011; Kettenmann & Ransom 2005).  
Astroglia expresses the intermediate filament glial fibrilliary acidic protein (GFAP), which is 
used as cellular marker of these cells (Ihrie & Alvarez-Buylla 2008).  Interestingly, astrocytes 
contain high number of GRs and MRs; consequently, astrocyte function and their GFAP 
expression are highly susceptible to glucocorticoids (Lambert et al. 2000; Rozovsky et al. 
1995). Some of the effects of glucocorticoids on gene and protein expression in astrocytes are 
summarized in the table 3.   
 
Protein / gene Function Glucocorticoid 
effect 
Reference 
Glial fibrilliary acidic 
protein (GFAP) 
Intermediate 
filament protein 
Upregulation (O'Callaghan et al. 
1991; Ramos-Remus et 
al. 2002) 
Glial glutamate 
transporter (GLT-1) 
Neurotransmitter 
recycling 
Upregulation (Reagan et al. 2004; 
Zschocke et al. 2005) 
Glutamine synthetase Neurotransmitter 
recycling 
Upregulation (Hansson 1989; 
Vardimon et al. 1999) 
Basic fibroblast growth 
factor (bFGF) 
Neurotrophic 
protein 
Upregulation (Niu et al. 1997) 
S100ǃ Ca2+-binding 
neurotrophic 
protein 
Upregulation (Van den Hove et al. 
2006) 
N-myc downstream-
regulated gene (Ndrg2)
Cell differentiation Upregulation (Nichols et al. 2005) 
 
Lipocortin-1 Anti-inflammatory 
protein 
Upregulation (McLeod & Bolton 
1995) 
Nerve growth factor 
(NGF) 
Neurotrophic 
protein 
Downregulation (Niu et al. 1997) 
Vimentin Intermediate 
filament 
Downregulation (Avola et al. 2004) 
Table 3. Effects of glucocorticoids on protein and gene expression in astrocytes. 
In vitro administration of dexamethasone, corticosterone or aldosterone inhibits astrocyte 
proliferation in a dose-dependent manner (Crossin et al. 1997). This effect seems to be 
mediated by neural cell adhesion molecules, which inhibit activation of mitogen-activated 
protein (MAP) kinase (Krushel et al. 1998).  The corticoid-induced inhibition of cell 
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proliferation and growth retardation may also be enhanced by a concomitant reduction in  
the production of insulin-like growth factor 1 (IGF-1) in parenchymal astrocytes (Adamo et 
al. 1988).  On the other hand, the overexpression of GFAP and chondroitin sulfate 
proteoglycans in reactive astrocytes has been related to a deficient neuronal repair and less 
neurite outgrowth.  Methylprednisolone can revert these adverse effects by downregulating 
astrocyte activation (Liu et al. 2008) and reducing the number of GFAP-expressing astroglia 
(Sabolek et al. 2006).  Further studies indicate that dexamethasone can modify hippocampal 
neuron development and survival by decreasing the mRNA levels of nerve growth factor 
(NGF) (Niu et al. 1997) and GFAP in hippocampus and neocortex (Aleong et al. 2003).  In 
contrast, other reports using corticosterone (Bridges et al. 2008), prednisone (Ramos-Remus 
et al. 2002) and deflazacort (Gonzalez-Castaneda et al. 2007) reported an increase in the 
number and cytoplasmic processes of hippocampal and cortical astrocytes.  The reason for 
these discrepancies is not well-known, but they appear to be mediated by dose- and region-
dependent phenomena (Gonzalez-Perez et al. 2001).  
Glucocorticoids not only modify the function of glial cells in adult stages, but also during 
prenatal development. Prenatal betamethasone administration delays both astrocyte and 
capillary tight junction maturation (Huang et al. 2001a), as well as the myelination in the 
corpus callosum (Huang et al. 2001b).  Remarkably, glucocorticoid effects are not limited to 
the modulation of cell morphology or molecular expression in neuroglia. Instead, they are 
key modulators of glycogen metabolism and neurotransmitter transporter homeostasis as 
demonstrated in several experimental models.  For instance, cortical astrocytes exposed to 
dexamethasone show a reduction of noradrenaline-induced glycogen synthesis (Allaman et 
al. 2004).  Prednisolone, betamethasone and dexamethasone inhibit the transporter uptake of 
monoamines producing effects on physiological and behavioral processes (Hill et al. 2010).  
The glial glutamate transporter-1 (GLT-1) is also affected by synthetic glucocorticoids.  In 
cortical astrocytes, dexamethasone provokes a marked increase in the GLT-1 transcription 
and GLT-1 protein levels (Zschocke et al. 2005).  GABAergic neurons are also affected by 
synthetic glucocorticoids that impair their rhythmic firing, which may lead to cognitive 
deficit (Hu et al. 2010).  Taken together, this evidence indicates that synthetic glucocorticoids 
exert a strong modulation on neural cells by modifying protein expression, neurite growth, 
cell proliferation, neurotransmitter uptake, neuronal firing, vasculature function and 
neuronal degeneration.  
4.1 Implications in autoimmune neurological disorders. Pathological features 
observed in patients upon GCs administration 
One major application of synthetic glucocorticoids is the treatment of acute and chronic 
neuroinflammatory disorders, such as multiple sclerosis, autoimmune encephalomyelitis, 
immune rejection, Parkinson’s disease, retinal degeneration and others.  Increasing evidence 
indicates that the therapeutic efficacy of glucocorticoids against autoimmune disorders may 
rely not only on their well-known anti-inflammatory effects, but also on their properties of 
neuro-gliomodulation (Gonzalez-Perez et al. 2007).  For instance, methylprednisolone has a 
synergistic effect with Nogo-66 receptor protein, which promotes functional recovery and 
axonal growth in a model of spinal cord contusion (Ji et al. 2005).  Methylprednisolone also 
mediates anti-apoptotic effects on oligodendrocytes by activating STAT5 proteins, which 
up-regulate a splicing isoform of the bcl-x gene (Xu et al. 2009).  On the other hand, 
prednisone contributes to attenuate experimental autoimmune encephalomyelitis by 
preventing the reduction of brain-derived neurotrophic factor (BDNF) and NGF mRNA 
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expression into the brain (Chen et al. 2009).  Promising results have also been obtained with 
dexamethasone and fluocinolone in several studies, i.e. dexamethasone reduces astroglial 
reactivity to implanted neuroprosthetic devices in rat cortex (Spataro et al. 2005), whereas 
intravitreous administration of fluocinolone attenuates retinal degeneration (Glybina et al. 
2010).  Further evidence suggests that dexamethasone produces immunosuppressive effects 
on the astrocyte response to interleukin-1-beta stimulation (Pousset et al. 1999) and 
counteracts blood–brain barrier failure by decreasing transendothelial permeability (Cucullo 
et al. 2004).  
Despite synthetic glucocorticoids have demonstrated an adequate safety profile, increasing 
clinical experience and experimental studies indicate that corticoids are able to promote 
cognitive dysfunction, anxiety, cerebral atrophy, depression and steroid psychosis.  One of 
the first studies that associated the glucocorticoid delivery with mood disorders in humans 
was reported in prednisone-treated asthmatic children (Bender et al. 1991).  However, adults 
are also affected by corticoids as demonstrated in healthy volunteers that, after receiving a 
high-dose prednisone or dexamethasone, showed mood changes and memory impairment 
(Keenan et al. 1996; Schmidt et al. 1999; Wolkowitz 1994).  Cerebral atrophy was reported 
after a long-term treatment with glucocorticoids in patients with no previous history of 
central nervous system affection (Bentson et al. 1978; Hara et al. 1981). Other immunologic 
disorders, such as systemic corticosteroid hypersensitivity (de Sousa et al. 2010; Rachid et al. 
2011), toxic epidermal necrolysis (Navarro Llanos et al. 1996) or urticaria-angioedema 
(Gomez et al. 2002), have also been associated with the administration of glucocorticoids.  
Under specific circumstances synthetic corticoids may impair or even potentiate the 
progress of neurological disorders as reported in experimental models of Alzheimer’s 
disease, hypoxia or prenatal glucocorticoid delivery.  This fact appears to be particularly 
important in neurodegenerative disorders related to oxysterol production such as 
Alzheimer's disease and multiple sclerosis.  Oxysterols are oxidized forms of cholesterol that 
provokes oligodendrocyte apoptosis.  Dexamethasone exacerbates the apoptotic effects of 
oxysterols on oligodendrocytes, resulting in secondary necrosis (Trousson et al. 2009).  
Cerebral vasculature is also altered by exposure to dexamethasone that may deteriorate 
hippocampal functions (Neigh et al. 2010).  In hypoxia models, dexamethasone increases the 
expression of Bnip3, a pro-apoptotic Bcl-2 family, which impairs hypoxic tissue damage 
(Sandau & Handa 2007). 
Neuronal function and survival are also affected by synthetic corticoids.  Dexamethasone 
increases oxidative stress and expression of monoamine oxidase A and B, resulting in a 
higher loss of dopaminergic neurons (Arguelles et al. 2010).  Oral administration of 
prednisone or deflazacort promotes neuronal degeneration of pyramidal neurons in CA1 
and CA3 hippocampal regions (Gonzalez-Castaneda et al. 2007; Gonzalez-Perez et al. 2007; 
Ramos-Remus et al. 2002).  Dexamethasone also decreases the number of neurons in the 
striatum (dorsomedial caudate-putamen) and hippocampus (dentate gyrus, CA1 and CA3 
subfields), which may account for some of the cognitive deficits seen following 
administration of glucocorticoids to healthy volunteers (Haynes et al. 2001).  Glucocorticoids 
also target the developing brain as reported in children exposed to synthetic glucocorticoids 
in uterus, who showed a reduction in fetal and, in some cases, newborn and infant HPA axis 
activity (Tegethoff et al. 2009).  Other studies indicate that prenatal dexa- or betamethasone 
exposure also affects postnatal cognitive functions (Hauser et al. 2007; Hauser et al. 2006), 
reduces the survival of cholinergic neurons (Emgard et al. 2007), and produces permanent 
changes in the cytoarchitecture within midbrain dopamine nuclei (McArthur et al. 2005).  
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Taken together, this evidence indicates that synthetic glucocorticoid may have detrimental 
effects on glial and neuronal integrity. Therefore, some authors have proposed that 
uncontrolled use of glucocorticoids may predispose to the development of a range of 
psychiatric and neurological conditions throughout life. 
5. Conclusion 
Synthetic glucocorticoids are a valuable therapeutic strategy against neuroinflammation and 
autoimmune disorders with neurological involvement.  In fact, anti-inflammatory strategies 
receive growing attention for their potential to prevent pathological deterioration in 
multiple sclerosis (the most prevalent chronic autoimmune disease of the central nervous 
system), Parkinson's disease, autoimmune encephalomyelitis and other severe neurological 
disorders.  Nevertheless, the uncontrolled use of glucocorticoids must be avoided because of 
their deleterious potential on cognition, neuronal survival and apoptosis induction.  Yet, in 
those clinical situations where glucocorticoid use is necessary, a continuous 
neuropsychological assessment is strongly recommended to detect a possible neurological 
deterioration. 
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